DEA Revokes Beverly Hills Doc's License Over Safety Risks
Published Date: 2/10/2025
Notice
Summary
Dr. David Bockoff from Beverly Hills had his DEA registration suspended and is now losing it because he was found to be a danger to public health and safety. After a fair hearing, the decision to revoke his registration was confirmed, meaning he can no longer legally handle controlled substances. This affects Dr. Bockoff directly and signals a serious step to protect the public, with no money penalties mentioned but a clear end to his DEA privileges.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
DEA Registration Revoked for Dr. Bockoff
Dr. David Bockoff (DEA registration No. BB4591839) had his DEA registration immediately suspended on October 25, 2022 and, after a hearing held January 19–24, 2023 and an ALJ recommendation on May 2, 2023, the Agency confirmed revocation in a Decision and Order published February 10, 2025. As a result, Dr. Bockoff can no longer legally handle or prescribe controlled substances; the notice does not mention any monetary penalties.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-02420 — Formations of, Acquisitions by, and Mergers of Bank Holding Companies
Some companies want to become or grow as bank holding companies by merging with or buying banks. If you’re involved in banking or interested, you can share your thoughts by March 12, 2025. These moves could change who controls certain banks and might affect local banking options and money flow.
Next: 2025-02422 — Potassium Chloride (KCl); Receipt of Application for Emergency Exemption
The Idaho State Department of Agriculture wants to use potassium chloride to fight Quagga mussels on 1.26 acres. Since this chemical isn’t EPA-approved yet, they asked for a quick emergency OK. Because it’s urgent and limited, EPA skipped the usual public comment but still welcomes info from anyone interested.